Atlas Trials

Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

Clinical trial NCT02741557 · COMPLETED

Trial details

NCT number
NCT02741557
Sponsor
ViiV Healthcare
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Infection, Human Immunodeficiency VirusHIV Infections
Start date
2016-05-11
Primary completion
2016-10-24
Enrollment
118

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.